Female Osteoporosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Female Osteoporosis. Basic parameters: 50 years — 75 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Performance of the Osteoporosis Self-Assessment Tool (OST) and Osteoporosis Risk Assessment Index (ORAI) in Predicting Osteoporosis in Postmenopausal Turkish Women
Overview
The aim of this study is to compare the Osteoporosis Risk Assessment Tool and the Osteoporosis Self-Assessment Tool with the gold standard DEXA in determining the risk of osteoporosis in the lumbar and femoral regions in female individuals in the Turkish population, and to investigate their sensitivity and specificity in the first stage of screening for the detection of female osteoporosis.
Detailed description
This study will be conducted as a single-center, retrospective study at the Physical Medicine and Rehabilitation Clinic of Kayseri City Hospital between January 2024 and January 2025. This study will include female patients aged 50-75 who underwent osteoporosis screening with DEXA at the Kayseri City Hospital FTR outpatient clinics between January 2021 and January 2024. Patient data will be obtained retrospectively from the hospital database. Sociodemographic data (age, height, weight, body mass index) and current laboratory data (complete blood count, biochemical values (fasting blood sugar, BUN, creatinine, AST, ALT, calcium, phosphorus, alkaline phosphatase, total protein, albumin, parathyroid hormone, vitamin D3, T4, TSH), and DEXA values (bone mineral density, lumbar vertebrae, and femoral neck and total femur T scores) will be recorded. The OST score will be calculated using body weight and age parameters. The ORAI score will be calculated using age, weight, and estrogen use from hospital data.
The data will be evaluated using the SPSS 24.0 software package. Descriptive statistical analyses will include calculations of mean, standard deviation, frequency, and percentages. In comparative statistics, the Student T-test or Mann Whitney U-test will be used to compare independent groups. Chi-square analysis will be applied to compare categorical variables. Pearson or Spearman correlation analyses will be applied to evaluate the relationship between variables. Both groups will be compared, and p\<0.05 will be considered statistically significant.
Primary outcome measures
- Dual-energy X-ray absorptiometry (DEXA) [Time frame: January 2021 - January 2024]
- Osteoporosis Self-Assessment Tool (OST) [Time frame: January 2021 - January 2024]
- Osteoporosis Risk Assessment Index (ORAI) [Time frame: January 2021 - January 2024]
Eligibility criteria
Inclusion criteria
- Postmenopausal women aged 50-75
- Patients who underwent imaging with the STRATOS DEXA device at Kayseri City Hospital
Exclusion criteria
- Patients younger than 50 or older than 75 years of age
- Patients with secondary osteoporosis
- Male patients
- Patients with uncontrolled severe comorbid conditions
- Patients with a history of pathological fractures
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07402772 · Female osteoporosis